Tositumomab  (Synonyms: 托西莫单抗; Anti-Human CD20 Recombinant Antibody; V10XA53)

Tositumomab (Anti-Human CD20 Recombinant Antibody) is a mouse-derived IgG2a monoclonal antibody, targeting to human CD20. Tositumomab can deplete B cells. Tositumomab can be used for the research of cancer, such as lymphoma^[1][2].

Mouse IgG2a

Mouse IgG2a kappa, Isotype Control

Human

MS4A1

Tositumomab (0.4-10 μg/mL, 15 mins) 在 SU-DHL-4 细胞中显示出强大的补体依赖的细胞毒性活性 (CDC)^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Tositumomab (₁₃₁I-tositumomab) (2,035 kBq) 可抑制人 Raji 淋巴瘤细胞注射的小鼠肿瘤模型中的肿瘤生长并延长其生存期^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

931  [NCBI]

P11836

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

147.298 kDa

192391-48-3

液体

Colorless to light yellow

托西莫单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG2a-lambda

• 
  Loaded Tositumomab on AHC2 biosensor, can bind CD20/MS4A1 Protein, Human (Trx-His, HY-P7896A) with an affinity constant of <1.000E-11 M as determined in BLI assay.

• [1]. Havlena GT, et al. Cure of Micrometastatic B-Cell Lymphoma in a SCID Mouse Model Using 213Bi-Anti-CD20 Monoclonal Antibody. J Nucl Med. 2023 Jan;64(1):109-116.  [Content Brief]

  [2]. Beers SA, et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood. 2008 Nov 15;112(10):4170-7.  [Content Brief]